Digital Biomanufacturing Market Synopsis:
\nDigital Biomanufacturing Market Size Was Valued at USD 19.89 Billion in 2023, and is Projected to Reach USD 66.13 Billion by 2032, Growing at a CAGR of 14.28% From 2024-2032.
\nBiomanufacturing with automation with AI\/ML and data analytics are the digital aspects that are part of the biomanufacturing processes. These technologies improve the capability in managing and operating biomanufacturing operations, especially for goods such as biopharmaceuticals, vaccines, and cell and gene therapies to be more productive and accurate, in addition to being amenable to real-time monitoring.
\nThe rapidly growing digital biomanufacturing market is a result of burgeoning interaction between biotechnology and digital technologies. The traditional biosynthesis method was immobile to automation, and most of the manufacturing was under manual control. However, advances in digital technologies have now revolutionalised these processes and created the conditions for enabling smart factories. Biomanufacturing 4.0 integrates artificial intelligence and big data and cloud computing to drive performance, improve quality of products, and meet strict guidelines. Technology also brings in use of sensors and data which means real time process monitoring improving on time utilization and productivity.
\nWith the current pressures on the biopharmaceutical sector cutting costs of production but without compromising on quality and the benefits of scale, digital biomanufacturing solutions are now critical. This is true specially for the manufacture of highly specialized biological commodities such as cell & gene therapies, monoclonal antibodies, recombinant proteins, etc., where accuracy is the essence. The market internationally is expected to grow significantly, driven by trends such as decentralised and agile manufacturing capabilities required to address increased demand for targeted therapies especially in cancer, orphan diseases and other long-term illnesses. Additionally, growth in the market is backed with federal and industrial capital towards building up the bio-manufacturing ecosystem with blended digital capabilities.<\/p>\n
Digital Biomanufacturing Market Trend Analysis:
\nShift Towards Automation in Biomanufacturing <\/p>\n
The automation that is now rapidly seeping its way into the field of digital biomanufacturing is revolutionizing it. Robotic applications are common in cell culture, material movement and bioreactor tracking and control. The change towards automating also eliminates one of the biggest factors for inefficiency that is human interference and also maintains the constant production throughout the 24 hours of operation. Consequently, they help minimize production constraints and accelerate the time to market for the biological products.<\/p>\n
In addition, automation assists biomanufacturers to continue meeting the required GMP and regulatory requirements. The major advantages of automated data collection and analysis is increased compliance with the quality standards deemed necessary by various regulatory bodies. Automation is also incorporated with smart cyber-twins, digital replicas of the manufacturing systems and processes that allow for anticipatory actions to be made where duration of downtimes due to mechanical breakdowns or poor performance is minimized.
\nExpansion of Cell and Gene Therapy Manufacturing <\/p>\n
One promising application in the digital biomanufacturing space is in the growth of cell and gene therapy manufacturing. Since these novel biotherapies can cure once untreatable diseases, there is a growing need towards the process improvement and manufacturing economy. Cell and gene therapies coming of age can transform patient care through digital technologies capable of enhancing the reproducibility and scalability of manufacturing through automation and real-time process control.<\/p>\n
This opportunity is backed by the regulatory agencies with the latter encouraging innovation in biomanufacturing. The provision of government support together with the possibilities to strengthen the control over the processes within the digital platforms will allow manufacturers to meet the growing demand for these therapies and provide the necessary quality at the same time. The potential is huge, especially because the portfolio of clinical stage gene and cell therapy assets is growing apace.
\nDigital Biomanufacturing Market Segment Analysis:
\nDigital Biomanufacturing Market is Segmented on the basis of Component, Application, End User, Deployment Mode, and Region
\nBy Component, Service segment is expected to dominate the market during the forecast period<\/p>\n
The digital biomanufacturing market can therefore be categorized in software, hardware and services. Software in this context is instrumental in process control and real-time monitoring, system and data analysis. Manufacturing execution systems and enterprise resource planning system are essential solution anthems in managing and coordinating biomanufacturing activities. These software solutions connect to sensors and devices and are able to offer valuable information for improving product quality and optimising processes. The market is expected to grow even further as advanced artificial intelligence solutions are included into software solutions that manufacturers look towards to increase efficiency.<\/p>\n
Other equipment include bioreactors, sensors, and automation equipment are part of the digital biomanufacturing equipment. The smart bioreactors that have to be provided with sensors shall be able to track the important process parameters such as, pH, temperature and DO level and make change in the process as accordingly. On the services side, consulting and system integration services are gradually becoming more popular as businesses need help in choosing the right technology solutions and adjusting work processes to meet the necessary standards.
\nBy Application, Cell & Gene Therapy segment expected to held the largest share <\/p>\n
The Digital Biomanufacturing applications are across some of the most strategic sectors such as Cell & Gene Therapy, Vaccines, Monoclonal Antibodies and Recombinant Proteins. Digitalization of production process in cell and gene therapy is beneficial in terms of improved control and increasing quantity of one-of-a-kind products. These conditions can be managed through digital portals conveniently making it easier to track cell cultures, a vital requirement for cell-based therapies.<\/p>\n
This is especially helpful in vaccine and monoclonal antibody products, where digital biomanufacturing reduces production complexity, especially in situations where demand surges, including pandemics. Digital technologies also enable accelerations of economies of scale in vaccine production; data analytics guarantee quality. The fact that it has been made possible to, digitize these processes contributes to reduction of development time and costs.
\nDigital Biomanufacturing Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
North America has the largest share in the digital biomanufacturing market today because this area has well-developed biopharmaceutical industry and focuses on the development of new technologies. The biopharmaceutical market in the United States and Canada has. Beken a fast adoption rate because of the available research and manufacturing facilities. Moreover, the zone has had a good investment in health care technologies; this has enhanced the innovation and adoption of health care technology in biomanufacturing systems.<\/p>\n
Favourable government policies and supportive regulations in the country have also supported North America\u2019s leadership. This one was signed in December 2016 and is known as 21st Century Cures Act, concept which aims at promoting innovation and simplifying regulation of ATMPs, including cell and gene therapies. This environment has enabled North America to continue leading in the advancement of digital biomanufacturing experiences.
\nActive Key Players in the Digital Biomanufacturing Market:<\/p>\n
Thermo Fisher Scientific (USA)<\/p>\n
Merck KGaA (Germany)<\/p>\n
Sartorius AG (Germany)<\/p>\n
Danaher Corporation (USA)<\/p>\n
Cytiva (USA)<\/p>\n
Lonza Group (Switzerland)<\/p>\n
Boehringer Ingelheim (Germany)<\/p>\n
GE Healthcare (USA)<\/p>\n
Samsung Biologics (South Korea)<\/p>\n
Fujifilm Diosynth Biotechnologies (Japan)<\/p>\n
Catalent, Inc. (USA)<\/p>\n
Wuxi Biologics (China)<\/p>\n
Others Active Player
\nKey Industry Developments in the Digital Biomanufacturing Market:<\/p>\n
In June 2024, BioM Conference is expected to organize 6th CIRP Conference on Biomanufacturing in Dresden, Germany, with an aim to promote AI and digital methods in biomanufacturing.<\/p>\n
In June 2023, Kaia Health launched Angela, a HIPAA-compliant, AI-powered voice-based digital care assistant, companion, and guide with the aim to enhance physical therapy experience of the patients.<\/p>\n
In March 2023, MindMaze launched a proprietary medical device called Izar across the US and Europe with an aim to improve the hand recovery post-stroke.<\/p>\n","protected":false},"excerpt":{"rendered":"
Biomanufacturing with automation with AI\/ML and data analytics are the digital aspects that are part of the biomanufacturing processes.<\/p>\n","protected":false},"featured_media":24050,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[257],"product_tag":[],"class_list":["post-26859","product","type-product","status-publish","has-post-thumbnail","product_cat-service-industry","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n